Previous 10 | Next 10 |
RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022 Meeting Pursuant to BLA Application for Dry Eye Syndrome PR Newswire ROCKVILLE, Md. , Dec. 17, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneR...
RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome PR Newswire ROCKVILLE, Md. , Nov. 29, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focuse...
Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting PR Newswire ROCKVILLE, Md. , Oct. 29, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), ...
Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis PR Newswire ROCKVILLE, Md. , Oct. 6, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("Reg...
New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease PR Newswire ROCKVILLE, Md. , Oct. 5, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company foc...
RegeneRx Licensee Acquired by Korean Biopharmaceutical Group PR Newswire ROCKVILLE, Md. , Sept. 27, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, ...
RegeneRx Issues Letter To Stockholders Update on Recent Financing, FDA Regulatory Process, Future Operations PR Newswire ROCKVILLE, Md. , July 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a cl...
RegeneRx Biopharmaceuticals (RGRX) JV ReGenTree plans to submit a pre-BLA meeting request to the U.S. FDA regarding its dry eye disease treatment RGN-259 within the third quarter.ReGenTree, the joint venture between RegeneRx and GtreeBNT, is working with a third party FDA...
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome PR Newswire ROCKVILLE, Md. , July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protectio...
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement PR Newswire ROCKVILLE, Md. , July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx") , a clinical-stage drug development company focused on tissue prot...
News, Short Squeeze, Breakout and More Instantly...
Regenerx Biopharms Inc Company Name:
RGRX Stock Symbol:
OTCMKTS Market:
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations PR Newswire ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development compa...
RegeneRx Receives Stockholder Approval for Reverse Stock Split PR Newswire ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development company focused o...
RegeneRx To Extend Consent Solicitation Vote PR Newswire ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and...